ProfoundBio is a biotechnology company that specializes in the development of novel therapeutics aimed at treating various forms of cancer. The company leverages its proprietary technology platform to identify and advance new cancer therapies through the drug development pipeline.

Tae Han

Xiao Shang

Baiteng Zhao

ProfoundBio

ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The Company’s clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA.

Xianfeng Qiyun

Gaorong Capital

K2VC

Chang'an Capital

Oriza Holdings

Sequoia Capital China

Lilly Asia Ventures

LYFE Capital

Surveyor Capital

T. Rowe Price

Ally Bridge Group

Piper Heartland Healthcare Capital

Janus Henderson Investors

LifeSci Venture Partners

Logos Capital

Medicxi

Are you going to be at #AACR2024 in San Diego? Don’t miss ProfoundBio’s presentations from our novel #ADC pipeline. Read more: https://lnkd.in/ga2ffDfq. #cancerresearch #biotech

Proud to share that ProfoundBio has secured $112 million in an oversubscribed Series B round, fueling our mission to advance novel cancer treatments, including advancing our flagship #ADC, rinatabart sesutecan (Rina-S) into late-stage clinical development. Deep gratitude to our esteemed life science investors for backing our vision. A big welcome to Andrew Lam, PharmD, Eric Dobmeier, and Enoch Kariuki, PharmD for joining our Board of Directors. With their guidance, we're diving deep into the next phase of innovation in #cancerresearch Learn more: https://lnkd.in/djG5g9EM 

#AntibodyDrugConjugates #Oncology #TargetedTherapy #SeriesBFinancing #BiotechInnovation

ProfoundBio is thrilled to announce the initiation of dosing in the Phase 1/2 clinical trial of PRO1107, marking a significant step forward in our efforts to develop antibody-drug conjugates (ADCs) with improved clinical outcomes for cancer patients. PRO1107 is a pioneering Protein Tyrosine Kinase 7 (PTK7)-targeted ADC that leverages our novel, proprietary hydrophilic MMAE-based linker-drug, aiming to set new standards in safety and efficacy for MMAE-based ADCs in the fight against cancer.

A heartfelt thank you to our dedicated investigators and the patients participating in this trailblazing research. Your involvement is pivotal in driving forward our mission to deliver groundbreaking treatments.

Read more: https://lnkd.in/gKXsEwsB

#ProfoundBio #ClinicalTrial #CancerResearch #InnovationInOncology #BiotechLinkedIn

📣 ProfoundBio is thrilled to announce that rinatabart sesutecan (Rina-S) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)!

See our press release for more info 👉 : https://lnkd.in/gx9MUXiJ

Metric
Company Name	ProfoundBio
Symbol
MSH ID	COM:PROFOUNDBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	32
Website	profoundbio.com
LinkedIn	profoundbio
Founders

Metric
Market Cap	795.51M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PROFOUNDBIO

ProfoundBio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue